IKT — Inhibikase Therapeutics, Inc.

Summary of Inhibikase Therapeutics Q2 2024 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: $5.0 million ($0.66 per share) for Q2 2024, an improvement from a net loss of $5.8 million ($0.94 per share) in Q2 2023.
• R&D Expenses: $3.1 million, down from $4.5 million in the prior year, primarily due to reduced costs associated with IkT-001Pro.
• SG&A Expenses: Increased to $2.0 million from $1.8 million, driven by higher legal and consulting fees.
• Cash Position: As of June 30, 2024, the company had $7.9 million in cash and equivalents, expected to fund operations into December 2024.

2. Strategic Updates and Business Highlights

• Clinical Progress: Enrollment for the Phase 2 201 trial of risvodetinib (risvo) in Parkinson's disease has been completed, with top-line data expected in November 2024.
• IkT-001Pro Development: The IND for IkT-001Pro targeting pulmonary arterial hypertension (PAH) was filed on August 9, 2024, with plans for a Phase 2b study.
• Focus on Disease Modification: Both risvodetinib and IkT-001Pro are positioned as potential disease-modifying therapies, with risvodetinib showing promise in halting Parkinson's progression and IkT-001Pro aiming to improve the safety profile of imatinib for PAH.

3. Forward Guidance and Outlook

• Upcoming Milestones: Anticipation of top-line results from the risvodetinib trial and the initiation of clinical development for IkT-001Pro in PAH.
• Phase 3 Trials: Plans for two Phase 3 trials for risvodetinib, targeting 300-400 patients total, with dosing expected to last up to 12 months.
• Financial Strategy: The company is exploring additional funding opportunities to support ongoing and future clinical trials, particularly for IkT-001Pro.

4. Bad News, Challenges, or Points of Concern

• Patient Management: There are concerns regarding the potential for patients to switch to symptomatic treatments during the gap between the completion of the risvodetinib trial and the launch of the open-label extension study.
• Financial Constraints: While the company has sufficient cash to fund operations until December 2024, additional funding will be necessary for the larger-scale trials, particularly for IkT-001Pro.
• Regulatory and Operational Risks: The delicate nature of the PAH patient population poses challenges in trial execution, and the company must ensure adequate infrastructure and funding to support the trial's demands.

5. Notable Q&A Insights

• Risvodetinib Data Expectations: The company is looking for evidence of safety and potential disease-modifying effects in the upcoming data release, which could support a direct transition to Phase 3 trials.
• Phase 2b Study Design: The Phase 2b study for IkT-001Pro is expected to include around 100 patients, with a focus on safety and tolerability, and may lead to a conditional approval pathway.
• Trial Execution Timeline: The timeline for starting the PAH trial is estimated at 9 to 12 months, contingent on securing funding and establishing necessary infrastructure.

Overall, Inhibikase Therapeutics is navigating a pivotal phase with significant clinical milestones ahead, while also facing financial and operational challenges that could impact its strategic initiatives.